Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

<p>Abstract</p> <p>Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome symptoms, which have a significant negative impact on...

Full description

Bibliographic Details
Main Authors: Randhawa Jasleen, Ostojic Alen, Vrhovac Radovan, Atallah Ehab, Verstovsek Srdan
Format: Article
Language:English
Published: BMC 2012-08-01
Series:Journal of Hematology & Oncology
Subjects:
JAK2 inhibitor
Myeloproliferative neoplasms
Myelofibrosis
JAK2V617F mutation
Splenomegaly
Online Access:http://www.jhoonline.org/content/5/1/43

Internet

http://www.jhoonline.org/content/5/1/43

Similar Items